Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Immunome (IMNM) Operating Expenses (2023 - 2025)

Historic Operating Expenses for Immunome (IMNM) over the last 3 years, with Q3 2025 value amounting to $60.1 million.

  • Immunome's Operating Expenses rose 1255.05% to $60.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $243.9 million, marking a year-over-year decrease of 2555.19%. This contributed to the annual value of $314.8 million for FY2024, which is 15483.29% up from last year.
  • According to the latest figures from Q3 2025, Immunome's Operating Expenses is $60.1 million, which was up 1255.05% from $50.5 million recorded in Q2 2025.
  • In the past 5 years, Immunome's Operating Expenses ranged from a high of $133.3 million in Q1 2024 and a low of $6.8 million during Q1 2023
  • For the 3-year period, Immunome's Operating Expenses averaged around $54.2 million, with its median value being $50.5 million (2025).
  • In the last 5 years, Immunome's Operating Expenses surged by 185066.57% in 2024 and then tumbled by 6432.71% in 2025.
  • Quarter analysis of 3 years shows Immunome's Operating Expenses stood at $98.5 million in 2023, then decreased by 12.97% to $85.7 million in 2024, then dropped by 29.83% to $60.1 million in 2025.
  • Its last three reported values are $60.1 million in Q3 2025, $50.5 million for Q2 2025, and $47.6 million during Q1 2025.